BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...
MIAMI--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet ...
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes ...
BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by ...
Brickell Biotech Inc (NASDAQ: BBI) has entered into an exclusive agreement with Carna Biosciences Inc to develop and commercialize Carna's portfolio of oral Stimulator Interferon Genes (STING) ...
Brickell Biotech Inc. said it has gathered $7 million in Series B funding to drive three novel drugs for common skin conditions through proof-of-concept clinical trials next year. The company, founded ...
Brickell Biotech Inc. said it has raised $10 million in Series C financing and launched new clinical studies of a treatment for axillary hyperhidrosis, or excessive underarm perspiration. Brickell has ...
Futures for Canada's main stock index edged higher on Wednesday after U.S. President Donald Trump extended the ceasefire with Iran indefinitely, though doubts lingered following reports of gunfire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results